BioWorld-International-2008-06-11

LONDON - Astex Therapeutics Ltd. sealed a deal worth a potential $500 million, licensing its fibroblast growth factor receptor (FGFR) inhibitor and agreeing on a drug discovery program around two cancer targets, with Janssen Pharmaceutica NV. (BioWorld International)

No Abstract

No Abstract

No Abstract

No Abstract

No Abstract

No Abstract

No Abstract

No Abstract

No Abstract